Heron Therapeuti Stock Performance
| HRTX Stock | USD 2.71 0.06 2.17% |
On a scale of 0 to 100, Heron Therapeuti holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.87, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Heron Therapeuti will likely underperform. Please check Heron Therapeuti's potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Heron Therapeuti's current trending patterns will revert.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Heron Therapeuti are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Heron Therapeuti showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.17) | Five Day Return (7.51) | Year To Date Return 43.39 | Ten Year Return (77.23) | All Time Return (99.53) |
Last Split Factor 1:20 | Last Split Date 2014-01-13 |
1 | Heron Therapeutics Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod | 01/24/2024 |
2 | 4D Molecular Therapeutics, Inc. Reports Q4 Loss, Misses Revenue Estimates | 02/29/2024 |
3 | Heron Therapeutics, Inc. Q4 2023 Earnings Call Transcript | 03/13/2024 |
4 | When Can We Expect A Profit From Heron Therapeutics, Inc. | 03/14/2024 |
5 | 1,400 attend St. Lawrence County Chambers Kids Expo | 03/18/2024 |
6 | The Boy and the Heron Hayao Miyazaki Movie to Stream On Netflix | 03/21/2024 |
7 | Heron Therapeutics Inc Stock What Does the Chart Say Tuesday - InvestorsObserver | 03/26/2024 |
8 | Congress Park Capital LLC Purchases 1209500 Shares of Heron Therapeutics, Inc. - Defense World | 04/01/2024 |
9 | Disposition of 62500 shares by Craig Collard of Heron Therapeuti subject to Rule 16b-3 | 04/03/2024 |
10 | Heron Therapeutics Share Price Crosses Above 200-Day Moving Average of 1.82 - MarketBeat | 04/10/2024 |
11 | Heron Therapeutics adds US56m to market cap in the past 7 days, though investors from five years ago are still down 87 | 04/12/2024 |
12 | Disposition of 42631 shares by Lisa Peraza of Heron Therapeuti subject to Rule 16b-3 | 04/15/2024 |
13 | Heron Therapeutics Zynrelef Eases Shareholder Pain - Seeking Alpha | 04/16/2024 |
| Begin Period Cash Flow | 15.4 M |
Heron |
Heron Therapeuti Relative Risk vs. Return Landscape
If you would invest 234.00 in Heron Therapeuti on January 20, 2024 and sell it today you would earn a total of 37.00 from holding Heron Therapeuti or generate 15.81% return on investment over 90 days. Heron Therapeuti is currently generating 0.3767% in daily expected returns and assumes 5.6184% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Heron, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Heron Therapeuti Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Heron Therapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Heron Therapeuti, and traders can use it to determine the average amount a Heron Therapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.067
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HRTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.62 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Heron Therapeuti is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Heron Therapeuti by adding it to a well-diversified portfolio.
Heron Therapeuti Fundamentals Growth
Heron Stock prices reflect investors' perceptions of the future prospects and financial health of Heron Therapeuti, and Heron Therapeuti fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Heron Stock performance.
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.87) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 539.68 M | ||||
| Shares Outstanding | 150.33 M | ||||
| Price To Earning | (5.15) X | ||||
| Price To Book | 12.60 X | ||||
| Price To Sales | 3.44 X | ||||
| Revenue | 127.04 M | ||||
| Gross Profit | (50.51 M) | ||||
| EBITDA | (107.72 M) | ||||
| Net Income | (110.56 M) | ||||
| Cash And Equivalents | 83.54 M | ||||
| Cash Per Share | 0.81 X | ||||
| Total Debt | 179.63 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.77 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (58.79 M) | ||||
| Earnings Per Share | (0.80) X | ||||
| Market Capitalization | 440.46 M | ||||
| Total Asset | 222.51 M | ||||
| Retained Earnings | (1.91 B) | ||||
| Working Capital | 109.09 M | ||||
| Current Asset | 134.75 M | ||||
| Current Liabilities | 19.73 M | ||||
About Heron Therapeuti Performance
To evaluate Heron Therapeuti Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Heron Therapeuti generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Heron Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Heron Therapeuti market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Heron's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 236.08 | 224.28 | |
| Return On Tangible Assets | (0.50) | (0.52) | |
| Return On Capital Employed | (0.77) | (0.81) | |
| Return On Assets | (0.50) | (0.52) | |
| Return On Equity | 3.25 | 3.42 |
Things to note about Heron Therapeuti performance evaluation
Checking the ongoing alerts about Heron Therapeuti for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Heron Therapeuti help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Heron Therapeuti had very high historical volatility over the last 90 days | |
| Heron Therapeuti has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 127.04 M. Net Loss for the year was (110.56 M) with loss before overhead, payroll, taxes, and interest of (50.51 M). | |
| Heron Therapeuti currently holds about 83.54 M in cash with (58.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Heron Therapeuti has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Heron Therapeutics Zynrelef Eases Shareholder Pain - Seeking Alpha |
- Analyzing Heron Therapeuti's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Heron Therapeuti's stock is overvalued or undervalued compared to its peers.
- Examining Heron Therapeuti's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Heron Therapeuti's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Heron Therapeuti's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Heron Therapeuti's stock. These opinions can provide insight into Heron Therapeuti's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Heron Therapeuti. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Heron Stock please use our How to Invest in Heron Therapeuti guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Heron Stock analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Heron Therapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heron Therapeuti. If investors know Heron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heron Therapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Revenue Per Share 0.92 | Quarterly Revenue Growth 0.14 | Return On Assets (0.25) | Return On Equity (24.09) |
The market value of Heron Therapeuti is measured differently than its book value, which is the value of Heron that is recorded on the company's balance sheet. Investors also form their own opinion of Heron Therapeuti's value that differs from its market value or its book value, called intrinsic value, which is Heron Therapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heron Therapeuti's market value can be influenced by many factors that don't directly affect Heron Therapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heron Therapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heron Therapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heron Therapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.